In addition, anlotinib showed antitumor activity on tumor cells carrying mutations in epidermal growth factor receptor (EGFR).10, 11 Phase I clinical trial has established the safety profile of anlotinib and identified commended dose of 12 mg once daily at the 2 weeks on treatment followed by 1 week off treatment schedule.11 In phase II, as a third‐line and above treatment for patients with advanced non‐small‐cell lung cancer (NSCLC), anlotinib has got an affirmatory efficacy on patients with advanced NSCLC, in ALTER0302 double‐blind, controlled trial.12 This evidence concerns the gene EGFR and neoplasm.